241 related articles for article (PubMed ID: 20406176)
1. Personalized medicine in oncology: a personal view with myths and facts.
Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
[TBL] [Abstract][Full Text] [Related]
2. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
3. Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?
Workman P
Curr Opin Investig Drugs; 2003 Dec; 4(12):1410-5. PubMed ID: 14763125
[TBL] [Abstract][Full Text] [Related]
4. Cancer trial assesses clinical benefit of gene-targeted treatment.
Katsnelson A
Nat Biotechnol; 2014 Apr; 32(4):306. PubMed ID: 24714466
[No Abstract] [Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. Progress towards personalized medicine.
Bates S
Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors: A new era of targeted therapy.
Tangutoori S; Baldwin P; Sridhar S
Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
[TBL] [Abstract][Full Text] [Related]
8. Drug Combination in Clinical Cancer Treatments.
Lu DY; Lu TR; Yarla NS; Wu HY; Xu B; Ding J; Zhu H
Rev Recent Clin Trials; 2017; 12(3):202-211. PubMed ID: 28782482
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives.
Metzger-Filho O; Moulin C; Awada A
Curr Clin Pharmacol; 2010 Aug; 5(3):166-77. PubMed ID: 20406173
[TBL] [Abstract][Full Text] [Related]
10. [The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
[TBL] [Abstract][Full Text] [Related]
11. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
[TBL] [Abstract][Full Text] [Related]
12. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments.
Yip HYK; Papa A
Cells; 2021 Mar; 10(3):. PubMed ID: 33809714
[TBL] [Abstract][Full Text] [Related]
13. [Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Chu DT
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):721-4. PubMed ID: 21163058
[No Abstract] [Full Text] [Related]
14. Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies.
Peng Y; Tao H; Gao Y; Yang Y; Chen Z
Curr Top Med Chem; 2021; 21(5):404-425. PubMed ID: 32543358
[TBL] [Abstract][Full Text] [Related]
15. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
17. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted therapeutics for breast cancer.
Hussain SA; Palmer DH; Spooner D; Rea DW
BioDrugs; 2007; 21(4):215-24. PubMed ID: 17628119
[TBL] [Abstract][Full Text] [Related]
19. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
[TBL] [Abstract][Full Text] [Related]
20. Community-driven development of a modified progression-free survival ratio for precision oncology.
Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
